Skip to main content
. 2021 Feb 15;118(8):e2019052118. doi: 10.1073/pnas.2019052118

Fig. 2.

Fig. 2.

ZMYND8 is overexpressed in ccRCC and is associated with the poor clinical outcome in patients. (A and B) Analysis of ZMYND8 mRNA (A) and protein (B) levels in human ccRCC and normal kidney tissues from the CPTAC ccRCC dataset. ***P < 0.001. (C) Kaplan–Meier survival analysis for ccRCC patients from the TCGA dataset using the log-rank test. Patients were divided by median expression level of ZMYND8 mRNA. HR, hazard ratio. (D) Using cBioportal, OncoPrint images of genomic alternations of the VHL gene were generated for 448 ccRCC samples from the TCGA dataset for which VHL status was available. (E and F) Kaplan–Meier survival analysis using the log-rank test for TCGA ccRCC patients for whom VHL status and prognosis data were available. Results for patients with VHL deletion/truncation/mutation are shown in E, and results for patients without VHL alterations are shown in F. Patients were divided by median expression level of ZMYND8 mRNA. (G) Representative ZMYND8 IHC staining images from a human ccRCC and normal kidney TMA. (H) Quantification of ZMYND8 protein level in normal kidney tissues and ccRCC specimens. **P < 0.01, chi-square test.